[Parapapillary autofluorescence as indicator for glaucoma].

A Viestenz; A Langenbucher; C Y Mardin

doi:10.1055/s-2005-858856

Home/Archive/PubMed

PubMed · 16639670

[Parapapillary autofluorescence as indicator for glaucoma].

A Viestenz·A Langenbucher·C Y Mardin

View original source ↗Export metadata ↓

Abstract

BACKGROUND: A pronounced fundus autofluorescence (lipofuscin) occurs in eyes with AMD. Parapapillary lipofuscin accumulation in the retinal pigment epithelial cells was observed in eyes with advanced glaucoma histologically. The aim of this study was to evaluate the parapapillary autofluorescence (PAF) in vivo in healthy eyes (controls), and in eyes with primary open angle glaucoma (POAG), pseudoexfoliation glaucoma (PSXG) or normal tension glaucoma (NTG). PATIENTS AND METHODS: Controlled cross-sectional analysis was performed on 281 consecutive eyes (98 controls, 95 POAG, 32 PSXG, 56 NTG). Eyes with fundus pathologies were excluded. The confocal scanning laser ophthalmoscope HRA II (Heidelberg Retina Angiograph II) was used after lipofuscin-excitation with an argon blue laser (488 nm) to detect PAF in the spectrum above 500 nm. PAF area and PAF distance to the optic nerve head were analyzed using the HRA standard software. Two experienced ophthalmologists classified independently the stage of glaucomatous optic nerve head atrophy (GONHA) using 15 degrees fundus photographs. RESULTS: Vital optic nerve heads had smaller PAF areas (stage 0: 0.07 +/- 0.09 mm (2)) in contrast to advanced stages of GONHA (stages 1 to 4: 0.27 +/- 0.46 mm (2); p < 0.001; logistic regression Cox and Snell: r = 0.7; p = 0.015). The PAF distance to the optic nerve head was lower in controls (0.12 +/- 0.08 mm) than in eyes with POAG, PSXG, or NTG (0.25 +/- 0.21 mm, Bonferroni: p < 0,004). The PAF area correlated significantly with the stage of GONHA (stage 1: 0.23 +/- 0.23 mm (2), stage 2: 0.24 +/- 0.19 mm (2), stages 3 and 4: 0.34 +/- 0.73 mm (2), p < 0.01). No significant difference of PAF area was found between the glaucoma types. However, the distance between PAF and optic nerve head was higher in POAG (0.28 +/- 0.26 mm) than in NTG (0.24 +/- 0.07 mm) or in PSXG (0.18 +/- 0.07 mm, Bonferroni: p < 0.03). CONCLUSIONS: A pronounced fundus autofluorescence was detected as a sign of increased lipofuscin accumulation in the parapapillary atrophic zone of eyes with POAG, PSXG, and NTG in contrast to controls. The PAF analysis may provide an indicator for glaucomas in the future.

Explore related subjects

Biomarkers Female Glaucoma Humans Image Interpretation, Computer-Assisted Lipofuscin Luminescence Luminescent Measurements Male Microscopy, Fluorescence Middle Aged Ophthalmoscopy Optic Disk Reproducibility of Results Sensitivity and Specificity Controlled Clinical Trial English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

A Viestenz, A Langenbucher, C Y Mardin. 2006. [Parapapillary autofluorescence as indicator for glaucoma].. https://doi.org/10.1055/s-2005-858856

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer.

BACKGROUND: Despite advances in metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) treatment, outcomes remain heterogeneous. Achieving a post-treatment undetectable prostate specific antigen (PSA) is a strong prognostic marker. We aimed to identify genomic and transcriptomic determinants of PSA response in a real-world clinical-genomic cohort. PATIENTS AND METHODS: Patients with mAPMS who underwent DNA (Tempus xT) and, in a subset, RNA (Tempus xR) sequencing were identified from the Tempus Lens database. Inclusion required stage IV disease within 90 days of sample collection and samples obtained within 12 months before or 3 months after treatment initiation. Patients with PSA at 6 months (n = 525) were classified as PSA-low (<0.1 ng/mL, n = 240) or PSA-high (≥0.1 ng/mL, n = 285). Overall survival (OS) was assessed by 6-month landmark analysis with delayed-entry adjustment. Logistic and Cox models were adjusted for clinical variables. Sensitivity analyses used a relative definition of > 95% PSA decline from baseline. RESULTS: Baseline PSA was lower in PSA-low versus PSA-high patients (24 vs 36 ng/mL, p = 0.01). SPOP (17% vs 11%) and ZFHX3 (2.5% vs 6%) alterations differed between groups, but neither persisted after adjustment. Using the relative definition, ZMYM3 and JAK1 alterations were independently associated with failure to achieve a deep PSA response. Expression of PSMA, TROP2, B7-H3, and STEAP1 did not differ between groups. PSA-low status was independently associated with improved OS, as was deep relative response. CONCLUSION: Deep PSA response at 6 months correlates with improved OS in mAPMS. Integrating molecular markers with PSA response may inform treatment intensification or de-escalation strategies.

Biomarkers↗

PubMed2026

Systemic treatment of advanced pancreatic cancer: A Comprehensive Review.

IMPORTANCE: Pancreatic adenocarcinoma (PDAC) is an uncommon but potentially catastrophic diagnosis with historically poor prognosis. It is the tenth most prevalent cancer in the US & UK. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide, with a five-year survival rate of approximately 10%. Despite increasing understanding of its molecular biology, systemic treatment options for advanced disease remain limited, and survival outcomes have improved only modestly over the past decade. OBSERVATIONS: This narrative review traces the evolution of systemic therapy for advanced PDAC from gemcitabine monotherapy through the landmark FOLFIRINOX (PRODIGE trial) and gemcitabine/nab-paclitaxel (MPACT trial) combination regimens, which remain the standard of care. Second-line options including liposomal irinotecan plus 5-FU/LV (NAPOLI-1) and maintenance olaparib for germline BRCA1/2-mutated disease (POLO) are also reviewed. Emerging data on sequential treatment strategies (SEQUENCE trial), biomarker-driven treatment selection (PRIMUS-001, PASS-01), and precision medicine approaches targeting actionable molecular subgroups, including dMMR/MSI-H, NTRK fusions, and homologous recombination deficiency are discussed. Real-world evidence comparing FOLFIRINOX and gemcitabine/nab-paclitaxel is critically appraised, including the challenges of patient selection, tolerance, and applicability outside clinical trial settings. CONCLUSION AND RELEVANCE: Despite incremental progress, the treatment landscape of advanced PDAC remains challenging. Molecular stratification and biomarker-driven precision oncology represent the most promising path forward. This review serves as a clinical reference for physicians managing advanced pancreatic cancer, highlighting current evidence, evidence limitations, and future research priorities including prospective biomarker-driven trials and improved access to genomic testing.

Biomarkers↗

PubMed2026

Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms.

In low- and middle-income countries, Alzheimer's disease (AD) constitutes a growing public health burden. However, AD biomarkers research remains underrepresented in African populations. This study assesses core biomarkers of AD and their relevance in the African context as potential aid in clinical diagnosis. Nigerian older adults from VALIANT cohort (n = 967) underwent biomarker quantification in plasma (p-tau217, GFAP, NfL, Aβ42 and Aβ40) employing both the Single Molecule Assay (Simoa, Quanterix) and Nucleic acid-Linked Immuno-Sandwich Assay (NULISA, Alamar). Biomarkers were associated with disease severity in clinical-diagnostic and clinical-biological groups, with stepwise increases of p-tau217, NfL and GFAP from cognitively unimpaired to dementia (p < 0.05). Results were consistent across platforms. Comparison between sexes showed higher biomarker levels in male participants across diagnostic groups. A significant effect of apoE-E4 proteotype on p-tau217 levels, after adjusting for age and sex was identified. These findings support the application of plasma AD biomarkers in the African context and the relevance of further AD biomarker research in diverse populations.

Biomarkers↗